OncoMatch/Clinical Trials/NCT04794972
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Is NCT04794972 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GNC-039 for recurrent glioma.
Treatment: GNC-039 — In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Tumor Agnostic
Disease stage
Grade: IIIIV (WHO)
recurrent high-grade glioma (WHO Grade III-IV), or other recurrent/refractory or metastatic solid tumors
Lab requirements
Blood counts
neutrophil absolute count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥90g/L
Kidney function
creatinine ≤1.5 ULN and creatinine clearance ≥50 mL/min; urinary protein ≤2+ or < 1000mg/24h
Liver function
AST and ALT ≤3.0×ULN; Total bilirubin ≤1.5×ULN (Gilbert's syndrome ≤3×ULN)
Hematological functions ... Renal function ... Liver functions ... Coagulation function: fibrinogen ≥1.5g/L; APTT ≤1.5×ULN; PT ≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify